<DOC>
	<DOCNO>NCT01280721</DOCNO>
	<brief_summary>ADPKD patient enrol Trial 156-04-251 receive repeat oral administration tolvaptan twice daily ( morning evening : 45mg/15mg , 60mg/30mg , 90mg/30mg ) .</brief_summary>
	<brief_title>A Study Investigate Long-term Safety Efficacy Tolvaptan Patients With Autosomal Dominant Polycystic Kidney Disease ( ADPKD ) Extension Trial 156-04-251 Japan</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients participate Trial 15604251 Japan CRF collection complete . Patients complete 3year repeated administration complete second followup visit patient whose treatment trial drug interupted due pregnancy complete second followup visit Trial 15604251 . Patients adverse event occur Trial 15604251 resolve orstabilized require followup . Patients eGFR less 15 mL/min/1.73 m2 Pregnant , breastfeeding , possibly pregnant woman woman plan become pregnant Patients receive investigational drug Tolvaptan within 30 day prior commencement administration tolvaptan Any patient , opinion principle investigator subinvestigators , participate study</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>53 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>